<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877990</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-077</org_study_id>
    <secondary_id>2020-004461-40</secondary_id>
    <secondary_id>U1111-1258-3838</secondary_id>
    <nct_id>NCT04877990</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis</brief_title>
  <official_title>An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of BMS-986165 in&#xD;
      participants who have previously been enrolled in a BMS-986165 Phase 2 study for moderate to&#xD;
      severe Crohn's disease or moderate to severe Ulcerative Colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 7, 2021</start_date>
  <completion_date type="Anticipated">June 4, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AEs leading to study discontinuation</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in vital signs: Blood pressure</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in vital signs: Heart rate</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in vital signs: Temperature</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in electrocardiogram (ECG) parameters: QRS interval</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in electrocardiogram (ECG) parameters: QTc interval</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in clinical laboratory results: Clinical Chemistry test</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant abnormalities in clinical laboratory results: Coagulation tests</measure>
    <time_frame>Up to Week 292</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Long-Term Extension Rollover Study: BMS-986165</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Long-Term Extension Rollover Study: BMS-986165</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Previously completed open-label extension treatment in one of the parent Crohn's disease&#xD;
        or ulcerative colitis studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any disease or medical condition that, in the opinion of the investigator, would make the&#xD;
        participant unsuitable for this study, would interfere with the interpretation of&#xD;
        participant safety or study results, or is considered unsuitable by the investigator for&#xD;
        any other reason&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <state>SAO Paulo</state>
        <zip>09715-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-794</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>03-712</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986165</keyword>
  <keyword>Crohn's Colitis</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Crohn's Iliocolitis</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

